Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Despite benefits, Merck's Keytruda falls short at NICE in urothelial carcinoma

americanpharmaceuticalreviewAugust 07, 2017

Tag: urothelial carcinoma , Merck's Keytruda

PharmaSources Customer Service